Microelectrode Arrays Emerge as a Powerful Tool for Detecting Cancer Drug Heart Damage

Cancer medicine is one of the great success stories of modern healthcare, with survival rates climbing steadily as chemotherapy regimens are refined and immunotherapies reshape what was once a grim prognosis. Yet this triumph has exposed an uncomfortable trade-off. Many of the drugs that save lives also damage the heart, and the risk falls disproportionately on the most vulnerable patients, particularly children and the elderly. Cardiotoxicity, ranging from subtle electrical disturbances to outright heart failure, can appear years after treatment ends, quietly eroding the very survival that oncology fought to secure. The collision of these two fields has given rise to cardio-oncology, a discipline dedicated to protecting the heart during cancer care, and more recently to its sharper-edged offshoot, precision cardio-oncology, which seeks patient-specific predictions of cardiac risk before the first dose is ever administered.

At the center of this emerging field sits a deceptively simple question: how do you test whether a cancer drug will disrupt the heartbeat without putting a patient in danger? The answer, for now, lies in the laboratory. Two categories of harm dominate the concern. The first is arrhythmia, the dangerous derangement of the heart’s electrical rhythm, which in its worst form can trigger sudden cardiac arrest. The second is contraction dysregulation, in which the mechanical beating of heart cells weakens or desynchronizes, foreshadowing the pump failure clinicians know as cardiomyopathy. Both can be modeled in vitro, in dishes of beating heart cells, but the accuracy of those models depends entirely on the tools used to interrogate them, and a recent review published in Frontiers in Electronics argues that those tools are overdue for an upgrade.

The current benchmark for preclinical rhythm safety testing is the Comprehensive in vitro Proarrhythmia Assay, or CiPA, an initiative launched in 2013 after a string of drugs were withdrawn from the market for causing fatal arrhythmias. CiPA replaced the old, blunt instruments of cardiac safety pharmacology with a tiered strategy that combines in vitro measurements, computer simulations, and clinical evidence to evaluate proarrhythmic risk with far greater specificity and sensitivity than legacy assays. Its scope deliberately stretches across a broad range of pharmaceutical compounds, and that includes chemotherapeutics, making it the natural starting point for anyone trying to predict how a cancer drug will behave in the electrical circuitry of the heart.

Under CiPA, the recommended in vitro toolbox includes several distinct technologies for measuring the electrical activity of heart cells. Transmembrane potential can be recorded directly through patch clamp techniques, including their automated, high-throughput variants, which offer exquisite sensitivity to the ion channel currents that drive each heartbeat. Impedance measurements track how cells deform as they contract, providing a window into mechanical function. Voltage-sensitive optical assays, including voltage indicator dyes and genetically encoded voltage indicators, convert electrical activity into light that cameras can capture across an entire cell culture at once. Alongside these, microelectrode arrays occupy a privileged position, reading out the extracellular electrical field generated by spontaneously beating cardiomyocytes through dozens or hundreds of embedded electrodes.

Critically, CiPA also specifies what the cells should be. The framework recommends pairing these measurement techniques with human induced pluripotent stem cell derived cardiomyocytes, abbreviated hiPSC-CMs, cells that begin as a patient’s own skin or blood cells before being reprogrammed into an embryonic-like state and coaxed into becoming beating heart muscle. This matters enormously for precision cardio-oncology, because hiPSC-CMs can be derived from individual cancer patients, meaning a cardiologist could one day test a chemotherapy regimen against a cellular replica of that specific patient’s heart before committing to a treatment plan. The combination of human genetics and laboratory throughput is what gives the modern approach its promise, and its urgency, as immunotherapies with novel cardiac side effects enter widespread clinical use.

Herein lies the gap the review identifies. While CiPA offers a mature framework for drug-induced arrhythmia, there are currently no guidelines in place for the in vitro assessment of cancer treatment induced arrhythmia specifically, no standardized protocols for evaluating contraction dysregulation caused by oncology drugs, and no agreed-upon methods for testing cardiotoxicity arising from cell-based cancer therapies, a rapidly growing class of treatments including engineered immune cells. Cancer therapy is not simply another branch of general pharmacology; chemotherapeutic and immunotherapeutic agents act through mechanisms that differ fundamentally from conventional small-molecule drugs, and the patient populations receiving them, the very young and the very old, have cardiac physiology that standard testing may not capture. Without standardized assays, each laboratory improvises, results are difficult to compare, and genuinely risky therapies may pass through the cracks.

The review’s central argument is that microelectrode arrays, or MEAs, are the technology best positioned to close that gap. A microelectrode array is exactly what the name implies: a dish, often glass or a flexible polymer substrate, embedded with a grid of microscopic electrodes that sit beneath or around a culture of cardiomyocytes. As the cells beat spontaneously, each depolarization generates an extracellular electrical signal that the electrodes record in real time, producing a continuous stream of data on firing rate, beat-to-beat timing, conduction velocity across the culture, and the emergence of irregular rhythms that signal proarrhythmic danger. Because the measurement is noninvasive, the same culture can be monitored for days or weeks, allowing chronic exposure studies that mimic real-world treatment courses rather than single-dose snapshots.

What elevates MEAs from useful to potentially transformative, the authors contend, is their capacity for simultaneous, multiparameter monitoring. Modern MEA platforms can track the electrophysiological activity of the culture, its contractile behavior, and morphological changes in the cells themselves, all within a single experiment. That matters because cancer treatment cardiotoxicity rarely announces itself through one channel alone. A drug might subtly slow conduction before it destabilizes rhythm, or impair contractile force while the electrical waveform still looks superficially normal. An assay that measures only one parameter can miss the early warning signs, whereas a platform that watches electricity, mechanics, and cell structure at once can build a composite picture of cardiac health, catching deterioration earlier and characterizing its mechanism more completely. Applied to both chemotherapeutic and immunotherapeutic agents, this integrated approach could form the backbone of the standardized testing protocols that cardio-oncology currently lacks.

The trajectory of the technology reflects its own history. Microelectrode arrays were born in classical electrophysiology, where they served for decades as a workhorse for recording neuronal and cardiac activity in slices and cultures. Their migration into cardiotoxicity testing represents both a technical and conceptual evolution: from observing what heart cells do naturally, to predicting what drugs will do to them. Combined with automated analysis, increasingly sophisticated human cell models, and the patient-specific potential of hiPSC-CMs, MEAs are evolving from a research instrument into a screening platform that could sit at the intersection of oncology and cardiology clinics, evaluating proposed cancer treatments against living human heart tissue before a single patient is exposed.

The stakes of getting this right are difficult to overstate. As cancer survival continues to improve, the population of long-term survivors living with treatment-damaged hearts grows in parallel, and pediatric patients cured of leukemia today may face decades of cardiovascular consequences tomorrow. A validated, standardized, in vitro pipeline for detecting cancer treatment induced arrhythmia and contraction dysregulation before clinical exposure would not merely protect future patients; it could also rescue promising oncology drugs whose cardiac liabilities are identifiable and manageable if caught early. The review’s message is that the tools exist, the cellular models exist, and the clinical need is urgent. What remains is the regulatory and scientific work of standardization, turning the humming electrodes of the microelectrode array into the sentinel that stands guard between a cancer cure and the heart that must carry the patient through it.

Subject of Research: In vitro assessment of cancer treatment-induced cardiotoxicity using microelectrode arrays

Article Title: Microelectrode arrays: from electrophysiology to integrated cancer treatment induced cardiotoxicity assessment

Article References: Microelectrode arrays: from electrophysiology to integrated cancer treatment induced cardiotoxicity assessment. (n.d.). https://doi.org/10.3389/felec.2026.1886715

Image Credits: AI Generated

DOI: 10.3389/felec.2026.1886715

Keywords: microelectrode arrays, cardiotoxicity, cardio-oncology, chemotherapy, immunotherapy, arrhythmia, CiPA, hiPSC-derived cardiomyocytes, patch clamp, contractility, drug screening, precision medicine